Works by Haruhiro Saito

Results: 68
    1
    2
    3

    Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC.

    Published in:
    Nature Communications, 2025, v. 16, n. 1, p. 1, doi. 10.1038/s41467-025-58186-7
    By:
    • Tanaka, Kentaro;
    • Sugisaka, Jun;
    • Shiraishi, Yoshimasa;
    • Watanabe, Yasutaka;
    • Daga, Haruko;
    • Azuma, Koichi;
    • Nishino, Kazumi;
    • Mori, Masahide;
    • Ota, Takayo;
    • Saito, Haruhiro;
    • Hata, Akito;
    • Sakaguchi, Tadashi;
    • Kozuki, Toshiyuki;
    • Akamatsu, Hiroaki;
    • Matsumoto, Hirotaka;
    • Tachihara, Motoko;
    • Wakuda, Kazushige;
    • Sato, Yuki;
    • Ozaki, Tomohiro;
    • Tsuchiya-Kawano, Yuko
    Publication type:
    Article
    4

    NOTCH1 and CREBBP co‐mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR‐mutated NSCLC: translational research of phase III IMPACT study.

    Published in:
    Molecular Oncology, 2024, v. 18, n. 2, p. 305, doi. 10.1002/1878-0261.13542
    By:
    • Ikeda, Satoshi;
    • Tsuboi, Masahiro;
    • Sakai, Kazuko;
    • Misumi, Toshihiro;
    • Akamatsu, Hiroaki;
    • Shoda, Hiroyasu;
    • Sakakura, Noriaki;
    • Nakamura, Atsushi;
    • Ohde, Yasuhisa;
    • Hayashi, Hidetoshi;
    • Okishio, Kyoichi;
    • Okada, Morihito;
    • Yoshino, Ichiro;
    • Okami, Jiro;
    • Takahashi, Kazuhisa;
    • Ikeda, Norihiko;
    • Tanahashi, Masayuki;
    • Tambo, Yuichi;
    • Saito, Haruhiro;
    • Toyooka, Shinichi
    Publication type:
    Article
    5
    6
    7

    Prognostic Significance of Plasma Neutrophil Extracellular Trap Levels in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.

    Published in:
    Biomedicines, 2024, v. 12, n. 8, p. 1831, doi. 10.3390/biomedicines12081831
    By:
    • Horaguchi, Shun;
    • Nakahara, Yoshiro;
    • Igarashi, Yuka;
    • Kouro, Taku;
    • Wei, Feifei;
    • Murotani, Kenta;
    • Udagawa, Seiichi;
    • Higashijima, Naoko;
    • Matsuo, Norikazu;
    • Murakami, Shuji;
    • Kato, Terufumi;
    • Kondo, Tetsuro;
    • Xiang, Huihui;
    • Kasajima, Rika;
    • Himuro, Hidetomo;
    • Tsuji, Kayoko;
    • Mano, Yasunobu;
    • Komahashi, Mitsuru;
    • Miyagi, Yohei;
    • Saito, Haruhiro
    Publication type:
    Article
    8

    Randomized phase II trial of S‐1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non‐small cell lung cancer.

    Published in:
    Cancer Medicine, 2021, v. 10, n. 2, p. 626, doi. 10.1002/cam4.3641
    By:
    • Shimokawa, Tsuneo;
    • Yamada, Kazuhiko;
    • Tanaka, Hiroshi;
    • Kubota, Kaoru;
    • Takiguchi, Yuichi;
    • Kishi, Kazuma;
    • Saito, Haruhiro;
    • Hosomi, Yukio;
    • Kato, Terufumi;
    • Harada, Daijiro;
    • Otani, Sakiko;
    • Kasai, Takashi;
    • Nakamura, Yoichi;
    • Misumi, Toshihiro;
    • Yamanaka, Takeharu;
    • Okamoto, Hiroaki
    Publication type:
    Article
    9
    10
    11
    12
    13
    14
    15

    Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors.

    Published in:
    Frontiers in Cell & Developmental Biology, 2024, p. 1, doi. 10.3389/fcell.2023.1324898
    By:
    • Yoshiro Nakahara;
    • Taku Kouro;
    • Satoru Motoyama;
    • Masatomo Miura;
    • Kazuma Fujita;
    • Yuka Igarashi;
    • Naoko Higashijima;
    • Norikazu Matsuo;
    • Hidetomo Himuro;
    • Feifei Wei;
    • Shun Horaguchi;
    • Kayoko Tsuji;
    • Yasunobu Mano;
    • Mitsuru Komahashi;
    • Haruhiro Saito;
    • Koichi Azuma;
    • Tetsuro Sasada
    Publication type:
    Article
    16

    Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors.

    Published in:
    Frontiers in Cell & Developmental Biology, 2024, p. 1, doi. 10.3389/fcell.2023.1324898
    By:
    • Yoshiro Nakahara;
    • Taku Kouro;
    • Satoru Motoyama;
    • Masatomo Miura;
    • Kazuma Fujita;
    • Yuka Igarashi;
    • Naoko Higashijima;
    • Norikazu Matsuo;
    • Hidetomo Himuro;
    • Feifei Wei;
    • Shun Horaguchi;
    • Kayoko Tsuji;
    • Yasunobu Mano;
    • Mitsuru Komahashi;
    • Haruhiro Saito;
    • Koichi Azuma;
    • Tetsuro Sasada
    Publication type:
    Article
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28

    Efficacy and safety of carboplatin and pemetrexed followed by maintenance with pemetrexed for elderly patients with advanced non‐squamous non‐small cell lung cancer: A single‐arm, open‐label, multicenter, phase II study.

    Published in:
    Asia Pacific Journal of Clinical Oncology, 2021, v. 17, n. 6, p. 486, doi. 10.1111/ajco.13488
    By:
    • Shinoda, Masahiro;
    • Shinkai, Masaharu;
    • Hara, Yu;
    • Tomaru, Kouji;
    • Manabe, Saki;
    • Murakami, Syuji;
    • Saito, Haruhiro;
    • Kobayashi, Nobuaki;
    • Miyazawa, Naoki;
    • Nishikawa, Masanori;
    • Kaneko, Takeshi
    Publication type:
    Article
    29
    30
    31

    Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016.

    Published in:
    2018
    By:
    • Ikeda, Satoshi;
    • Kato, Terufumi;
    • Ogura, Takashi;
    • Sekine, Akimasa;
    • Oda, Tsuneyuki;
    • Masuda, Noriyuki;
    • Igawa, Satoshi;
    • Katono, Ken;
    • Otani, Sakiko;
    • Yamada, Kouzo;
    • Saito, Haruhiro;
    • Kondo, Tetsuro;
    • Hosomi, Yukio;
    • Nakahara, Yoshiro;
    • Nishikawa, Masanori;
    • Utumi, Keiko;
    • Misumi, Yuki;
    • Yamanaka, Takeharu;
    • Sakamaki, Kentaro;
    • Okamoto, Hiroaki
    Publication type:
    journal article
    32
    33
    34
    35
    36
    37
    38

    A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.

    Published in:
    Clinical Lung Cancer, 2024, v. 25, n. 3, p. 266, doi. 10.1016/j.cllc.2024.03.003
    By:
    • Garon, Edward B.;
    • Byoung Chul Cho;
    • Luft, Alexander;
    • Alatorre-Alexander, Jorge;
    • Geater, Sarayut Lucien;
    • Dmytro Trukhin;
    • Sang-We Kim;
    • Ursol, Grygorii;
    • Hussein, Maen;
    • Louise Lim, Farah;
    • Cheng-Ta Yang;
    • Araujo, Luiz Henrique;
    • Haruhiro Saito;
    • Reinmuth, Niels;
    • Kohlmann, Milena;
    • Lowery, Caitlin;
    • Mann, Helen;
    • Peters, Solange;
    • Mok, Tony S.;
    • Johnson, Melissa L.
    Publication type:
    Article
    39

    A Phase II Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q).

    Published in:
    Clinical Lung Cancer, 2024, v. 25, n. 1, p. 85, doi. 10.1016/j.cllc.2023.09.006
    By:
    • Shinji Nakamichi;
    • Kaoru Kubota;
    • Kotone Matsuyama;
    • Toshihiro Misumi;
    • Toshiyuki Kozuki;
    • Shunichi Sugawara;
    • Katsuhiko Naoki;
    • Nobuaki Kobayashi;
    • Takehito Shukuya;
    • Tsuneo Shimokawa;
    • Masashi Ishihara;
    • Hiroshi Wakui;
    • Yukio Hosomi;
    • Hiroshi Tanaka;
    • Haruhiro Saito;
    • Shinobu Hosokawa;
    • Yuichi Takiguchi;
    • Takashi Kasai;
    • Hiroshi Nokihara;
    • Ryo Morita
    Publication type:
    Article
    40
    41
    42

    Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non‐squamous, non‐small cell lung cancer: TORG (thoracic oncology research group) 1321.

    Published in:
    Cancer Medicine, 2023, v. 12, n. 14, p. 14988, doi. 10.1002/cam4.6135
    By:
    • Kasai, Takashi;
    • Mori, Kiyoshi;
    • Nakamura, Yoichi;
    • Seki, Nobuhiko;
    • Ichikawa, Yasuko;
    • Saito, Haruhiro;
    • Kondo, Tetsuro;
    • Nishikawa, Kazuo;
    • Otsu, Satoshi;
    • Bessho, Akihiro;
    • Tanaka, Hiroshi;
    • Yamaguchi, Hiroyuki;
    • Kaburagi, Takayuki;
    • Imai, Hisao;
    • Mori, Keita;
    • Ohtake, Junya;
    • Okamoto, Hiroaki
    Publication type:
    Article
    43

    Multi-omics analysis-based clinical and functional significance of a novel prognostic and immunotherapeutic gene signature derived from amino acid metabolism pathways in lung adenocarcinoma.

    Published in:
    Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1361992
    By:
    • Xiang, Huihui;
    • Kasajima, Rika;
    • Azuma, Koichi;
    • Tagami, Tomoyuki;
    • Hagiwara, Asami;
    • Nakahara, Yoshiro;
    • Saito, Haruhiro;
    • Igarashi, Yuka;
    • Wei, Feifei;
    • Ban, Tatsuma;
    • Yoshihara, Mitsuyo;
    • Nakamura, Yoshiyasu;
    • Sato, Shinya;
    • Koizume, Shiro;
    • Tamura, Tomohiko;
    • Sasada, Tetsuro;
    • Miyagi, Yohei
    Publication type:
    Article
    44

    Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti‐PD‐1 inhibitor.

    Published in:
    International Journal of Cancer, 2019, v. 144, n. 5, p. 1170, doi. 10.1002/ijc.31923
    By:
    • Matsuo, Norikazu;
    • Azuma, Koichi;
    • Hattori, Satoshi;
    • Ohtake, Junya;
    • Kawahara, Akihiko;
    • Ishii, Hidenobu;
    • Tokito, Takaaki;
    • Yamada, Kazuhiko;
    • Shibata, Yuji;
    • Shimokawaji, Tadasuke;
    • Kondo, Tetsuro;
    • Kato, Terufumi;
    • Saito, Haruhiro;
    • Yamada, Kouzo;
    • Sasada, Tetsuro;
    • Hoshino, Tomoaki
    Publication type:
    Article
    45

    First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.

    Published in:
    Japanese Journal of Clinical Oncology, 2024, v. 54, n. 4, p. 452, doi. 10.1093/jjco/hyad195
    By:
    • Imai, Hisao;
    • Kijima, Takashi;
    • Azuma, Koichi;
    • Kishi, Kazuma;
    • Saito, Haruhiro;
    • Yamaguchi, Teppei;
    • Tanizaki, Junko;
    • Yoneshima, Yasuto;
    • Fujita, Kohei;
    • Watanabe, Satoshi;
    • Kitazono, Satoru;
    • Fukuhara, Tatsuro;
    • Hataji, Osamu;
    • Toi, Yukihiro;
    • Mizutani, Hideaki;
    • Hamakawa, Yusuke;
    • Maemondo, Makoto;
    • Ohsugi, Tomoyuki;
    • Suzuki, Keisuke;
    • Horinouchi, Hidehito
    Publication type:
    Article
    46
    47

    A phase II study of weekly carboplatin and concurrent radiotherapy in older adults with locally advanced non‐small cell lung cancer (LOGIK1902).

    Published in:
    Thoracic Cancer, 2024, v. 15, n. 29, p. 2128, doi. 10.1111/1759-7714.15444
    By:
    • Harada, Taishi;
    • Sasaki, Tomonari;
    • Ishii, Hidenobu;
    • Takemoto, Shinnosuke;
    • Hisamatsu, Yasushi;
    • Saito, Haruhiro;
    • Yoneshima, Yasuto;
    • Komiya, Kazutoshi;
    • Kashiwabara, Kosuke;
    • Naoki, Katsuhiko;
    • Ogawa, Tomohiro;
    • Takeoka, Hiroaki;
    • Saruwatari, Koichi;
    • Ito, Kensaku;
    • Tsuchiya‐Kawano, Yuko;
    • Mizuno, Keiko;
    • Shimose, Takayuki;
    • Shioyama, Yoshiyuki;
    • Okamoto, Isamu
    Publication type:
    Article
    48
    49
    50